

Published in final edited form as:

Mol Microbiol. 2005 October ; 58(2): 565–579. doi:10.1111/j.1365-2958.2005.04852.x.

***Agrobacterium tumefaciens* oncogenic suppressors inhibit T-DNA and VirE2 protein substrate binding to the VirD4 coupling protein**

Eric Cascales^{1,†}, Krishnamohan Atmakuri¹, Zhenying Liu², Andrew N. Binns², and Peter J. Christie^{1,*}

¹ Department of Microbiology and Molecular Genetics, University of Texas-Houston, Medical School, Houston, TX 77030, USA

² Plant Science Institute, Department of Biology, University of Pennsylvania, Philadelphia, PA 19104-6018, USA

Summary

Agrobacterium tumefaciens uses a type IV secretion (T4S) system composed of VirB proteins and VirD4 to deliver oncogenic DNA (T-DNA) and protein substrates to susceptible plant cells during the course of infection. Here, by use of the Transfer DNA Immuno-Precipitation (TrIP) assay, we present evidence that the mobilizable plasmid RSF1010 (IncQ) follows the same translocation pathway through the VirB/D4 secretion channel as described previously for the T-DNA. The RSF1010 transfer intermediate and the Osa protein of plasmid pSa (IncW), related in sequence to the FiwA fertility inhibition factor of plasmid RP1 (IncP α), render *A. tumefaciens* host cells nearly avirulent. By use of a semi-quantitative TrIP assay, we show that both of these ‘oncogenic suppressor factors’ inhibit binding of T-DNA to the VirD4 substrate receptor. Both factors also inhibit binding of the VirE2 protein substrate to VirD4, as shown by coimmunoprecipitation and bimolecular fluorescence complementation assays. Osa fused to the green fluorescent protein (GFP) also blocks T-DNA and VirE2 binding to VirD4, and Osa-GFP colocalizes with VirD4 at *A. tumefaciens* cell poles. RSF1010 and Osa interfere specifically with VirD4 receptor function and not with VirB channel activity, as shown by (i) TrIP and (ii) a genetic screen for effects of the oncogenic suppressors on pCloDF13 translocation through a chimeric secretion channel composed of the pCloDF13-encoded MobB receptor and VirB channel subunits. Our findings establish that a competing plasmid substrate and a plasmid fertility inhibition factor act on a common target, the T4S receptor, to inhibit docking of DNA and protein substrates to the translocation apparatus.

Introduction

Agrobacterium tumefaciens uses the VirB/D4 type IV secretion (T4S) system to translocate DNA and protein effector molecules to plant cells during infection (Zhu *et al.*, 2000; Cascales and Christie, 2003). The VirB/D4 T4S system is assembled from 11 VirB proteins, termed the mating pair formation (Mpf) proteins (Lessl *et al.*, 1993), and the VirD4 coupling protein (T4CP) (Ding *et al.*, 2003; Gomis-Ruth *et al.*, 2004), also termed the substrate receptor (Atmakuri *et al.*, 2003; Cascales and Christie, 2004a). This system is a *bona fide* conjugation apparatus, as shown by its capacity to deliver oncogenic transfer DNA (T-DNA) as well as the mobilizable plasmid RSF1010 (IncQ) to target cells through a cell-contact-dependent

*For correspondence. E-mail peter.j.christie@uth.tmc.edu; Tel. (+1) 713 500 5440; Fax (+1) 713 500 5499.

[†]Present address: Laboratoire d'Ingénierie des Systèmes Macromoléculaires, Institut de Biologie Structurale et Microbiologie, Centre National de la Recherche Scientifique, 31, Chemin Joseph Aiguier, 13402 Marseille Cedex 20, France.

mechanism (Buchanan-Wollaston *et al.*, 1987; Fullner, 1998). Studies of the VirB/D4 T4S system and of related conjugation systems, e.g. F (IncF), RP4 (IncP α), R388 (IncW) and pKM101 (IncN), have identified several early steps of conjugation (Lawley *et al.*, 2004; Christie and Cascales, 2005; Shroder and Lanka, 2005). DNA transfer initiates when the relaxase and auxiliary factors bind at the origin of transfer (*oriT*) sequence of a DNA substrate to form the relaxosome (Pansegrau and Lanka, 1996). The relaxosome catalyses the single-stranded (ss) cleavage of the DNA strand destined for transfer, whereupon the relaxase remains covalently bound to the 5' end of ssDNA substrate (Lessl and Lanka, 1994). The DNA substrate then docks at the T4CP via translocation signals carried by the relaxase and, for some systems, other processing components of the relaxosome (Simone *et al.*, 2001; Schroder *et al.*, 2002; Llosa *et al.*, 2003; Beranek *et al.*, 2004; Vergunst *et al.*, 2005). Finally, the T4CP acts together with the Mpf proteins, e.g. the VirB subunits, to mediate transfer of the nucleoprotein particle across the cell envelope (Cascales and Christie, 2004a). Conjugation machines also translocate protein substrates independently of DNA. For example, the *A. tumefaciens* VirB/D4 T4S system delivers several effector proteins, e.g. VirE2, VirE3 and VirF, to susceptible plant cells during infection (Vergunst *et al.*, 2000; 2005; Schrammeijer *et al.*, 2003). As shown for the T-DNA substrate, VirE2 also docks at the VirD4 receptor for translocation through this secretion channel (Atmakuri *et al.*, 2003).

Conjugative plasmids often encode factors that inhibit the transfer of coresident plasmids (Olsen and Shipley, 1975; Yusoff and Stanisich, 1984). Such fertility inhibition factors appear to fall into two broad classes, those acting to repress expression of transfer (*tra*) genes (Gasson and Willetts, 1976; Tanimoto and Iino, 1983), and those functioning at a step in the translocation pathway subsequent to Mpf subunit synthesis and assembly of the conjugation apparatus (Yusoff and Stanisich, 1984; Winans and Walker, 1985). Fertility inhibition via control of *tra* gene regulation has been extensively characterized for the F plasmid *finOP* inhibition system (van Biesen and Frost, 1994; Penfold *et al.*, 1996; Ghetu *et al.*, 2000). In contrast, little is known about the mechanism(s) by which fertility inhibition factors act downstream of T4S machine assembly (Lawley *et al.*, 2004). In *A. tumefaciens*, two factors have been shown to render wild-type (WT) cells nearly or completely avirulent, a phenomenon termed 'oncogenic suppression' (Close and Kado, 1991; Ward *et al.*, 1991). One factor is the RSF1010 transfer intermediate composed of the MobA relaxase covalently bound to the 5' end of the transferred ssDNA (R-strand) (Ward *et al.*, 1991; Stahl *et al.*, 1998). The second is the Osa protein encoded by the IncW plasmid pSa (Close and Kado, 1991). Osa does not affect accumulation or membrane association of VirB proteins (Chen and Kado, 1994; 1996). Moreover, Osa shares sequence similarities to FiwA, a fertility inhibition factor of IncP α plasmids that interferes with transfer of coresident IncQ and IncW plasmids (Chen and Kado, 1994; Fong and Stanisich, 1989). It can thus be postulated that Osa represents a class of fertility inhibition factors acting after T4S machine biogenesis to block one or more steps of translocation.

Studies exploring the inhibition mechanism(s) of RSF1010 and Osa have exploited the early finding that two avirulent strains, one deleted of the T-DNA and a second lacking a gene for a protein substrate, e.g. VirE2, incite tumour formation when coinoculated onto plant wound sites (Otten *et al.*, 1984). The simplest explanation for these findings is that these strains translocate the requisite complement of tumour-inducing T-DNA and protein substrates into the same plant cell (Christie *et al.*, 1988; Binns *et al.*, 1995). Such mixed infection experiments with Δ T-DNA or *virE2* mutant strains harbouring RSF1010 or a plasmid producing the Osa protein supplied evidence that both suppressor factors inhibit VirE2 translocation (Binns *et al.*, 1995; Lee *et al.*, 1999), whereas only RSF1010 inhibits T-DNA transfer (Binns *et al.*, 1995; Lee and Gelvin, 2004). Osa does, however, strongly inhibit intercellular transfer of other protein substrates, VirE3 and VirF (Schrammeijer *et al.*, 2003), as shown by a Cre recombinase (CRAfT) assay (Vergunst *et al.*, 2000).

In this study, we sought to define the mechanistic bases underlying ‘oncogenic suppression’. We present evidence that the RSF1010 substrate follows the same translocation pathway through the VirB/D4 secretion channel as recently described for the T-DNA substrate (Cascales and Christie, 2004a). We further report that the RSF1010 transfer intermediate and Osa suppress *A. tumefaciens* oncogenesis specifically by interfering with T-DNA and VirE2 substrate binding to the VirD4 receptor. The promiscuous plasmid RSF1010 and the pSa-encoded Osa fertility inhibition factor thus act on a common target, the T4S receptor, to inhibit substrate transfer through T4S machines.

Results

Plasmid RSF1010 (IncQ) follows the same translocation route as T-DNA through the VirB/D4 T4S system

The T-DNA transfer pathway has been depicted as a series of spatially and temporally ordered close contacts with six VirB/D4 channel subunits – VirD4, VirB11, VirB6, VirB8, VirB2 and VirB9, as shown with the Transfer DNA ImmunoPrecipitation (TrIP) assay (Cascales and Christie, 2004a). We first tested whether a mobilizable RSF1010 (IncQ) derivative, pML122 (Fullner, 1998), establishes similar channel subunit contacts during translocation through the VirB/D4 T4S system. To avoid possible competitive effects of a coresident T-DNA substrate, TrIP assays were carried out with *A. tumefaciens* strain LBA4404 (Δ T-DNA) harbouring pML122. Intact cells were treated with formaldehyde (FA) and detergent solubilized, and then material precipitated with antibodies to the Vir proteins was subjected to polymerase chain reaction (PCR) amplification to detect coprecipitation of cross-linked channel subunit–pML122 substrate complexes. As a non-substrate DNA control, we included primers for amplification of the *repAB* locus from pTiAch5 in the PCR amplification reaction. We further confirmed that antibodies to the VirD2 relaxase, which is not required for RSF1010 transfer (Buchanan-Wollaston *et al.*, 1987; Fullner, 1998), did not precipitate detectable levels of the pML122 or pTiAch5 plasmid fragments from LBA4404 or LBA4404(pML122) cell extracts (Fig. 1A).

Antibodies to the six putative VirB/D4 channel subunits named above specifically precipitated the *mobA* fragment carried by the pML122 substrate from extracts of the FA-treated cells (Fig. 1B and C). This fragment was undetectable in material precipitated with antibodies to the remaining six VirB proteins – VirB1, VirB3, VirB4, VirB5, VirB7, VirB10 – or to another postulated machine component VirJ (Pantoja *et al.*, 2002) (Fig. 1C). This profile of RSF1010 substrate–channel subunit contacts matched that obtained previously for the T-DNA substrate (Cascales and Christie, 2004a). Further TrIP studies established that individual *virB* and *virD4* null mutations blocked translocation of the pML122 substrate at the same stages as determined previously for the T-DNA (Cascales and Christie, 2004a; data not shown). We therefore conclude that the T-DNA and IncQ plasmid transfer intermediates follow the same route during translocation through the VirB/D4 secretion channel.

The IncQ plasmid inhibits T-DNA binding to the VirD4 receptor

Wild-type *A. tumefaciens* strain A348 incites abundant tumour formation on *Kalanchoe daigremontiana* leaves, whereas the isogenic strain harbouring an RSF1010 replicon is almost avirulent (Fig. 2A; Ward *et al.* 1991; Binns *et al.*, 1995). In view of the above evidence that T-DNA and pML122 substrates share the same VirB/D4 translocation pathway, we tested whether pML122 inhibits one or more steps of T-DNA translocation. These steps include: (i) T-DNA processing by the VirD2 relaxase, (ii) T-DNA docking at the VirD4 receptor and (iii) T-DNA transfer through the VirB/D4 secretion channel. Substrate processing and channel subunit contacts were monitored by TrIP and the modified QTrIP assay (Cascales and Christie, 2004a). This latter assay is based on radiolabelling of PCR products generated from

immunoprecipitated material to quantify levels of recovered substrate (see *Experimental procedures*).

Anti-VirD2 antibodies precipitated similar levels of the T-DNA transfer intermediate from A348 and A348(pML122) cells, showing that the IncQ plasmid does not affect VirD2 processing at T-DNA border repeat sequences (Fig. 2B). In striking contrast, the anti-VirD4 antibodies precipitated a very low level of T-DNA substrate from extracts of A348(pML122) compared with A348. The level of T-DNA precipitated with the VirD4 receptor in the presence of the IncQ plasmid was approximately one-tenth that in its absence, as determined by QTrIP (Fig. 2C). Of further interest, the anti-VirD4 antibodies precipitated an abundant amount of pML122 from A348(pML122), approximately nine times that of precipitated T-DNA (Fig. 2C).

The above findings suggest that the pML122 substrate outcompetes the T-DNA substrate for binding to the VirD4 receptor (Fig. 2C). Next, we sought to determine whether pML122 additionally disrupts passage of the T-DNA through the VirB/D4 secretion channel. However, antibodies to VirB11, VirB6, VirB8, VirB2 and VirB9 precipitated T-DNA and pML122 at approximately the same 1 to 9 ratio as obtained with antibodies to VirD4 (Fig. 2C). The IncQ plasmid thus appears to specifically disrupt T-DNA substrate-receptor binding without further downstream effects on T-DNA translocation. Supporting genetic evidence that the inhibitory effect of RSF1010 is restricted to substrate docking at the T4S receptor is presented below.

VirB9, VirB10 and VirB11 overproduction confer altered substrate selection

Ward *et al.* (1991) reported that the suppressive effects of RSF1010 can be partially reversed by the co-overproduction of VirB9, VirB10 and VirB11 (Fig. 2A). In agreement with this finding, antibodies to VirD4 and each of the five presumptive VirB channel subunits precipitated T-DNA at appreciably higher levels from extracts of the VirB9-VirB11 overproducing strain A348(pML122, pED9) than from A348(pML122) (Fig. 2C). Of further interest, these antibodies precipitated the pML122 substrate from A348(pML122, pED9) at diminished levels compared with A348(pML122). In Fig. 2C, the amount of T-DNA or RSF1010 substrate recovered from each strain is presented as a fraction of total T-DNA recovered with the same antibody from WT A348. Whereas the amount of total substrate (T-DNA plus RSF1010) recovered from A348(pML122) approximated the level of T-DNA from A348, the amount of total substrate recovered from A348(pML122, pED9) was reproducibly approximately 5% higher than from the WT strain (data not shown). This finding is consistent with an earlier proposal that VirB9, VirB10 and VirB11 are rate limiting for assembly of functional VirB/D4 T4S machines (Ward *et al.*, 1991). Yet, this small increase in substrate binding does not account for the pronounced approximately threefold increase in T-DNA binding and corresponding decrease in pML122 binding to the VirD4 and VirB channel subunits upon VirB overproduction (Fig. 2C). These findings and results of mutational analyses (see below) support a proposal that VirB proteins act in conjunction with VirD4 to modulate substrate selection and trafficking through the secretion channel (see *Discussion*).

The IncQ transfer intermediate inhibits T-DNA binding to the VirD4 receptor

Processing at the *oriT* sequence by the MobA relaxase of RSF1010 is required for suppression of *A. tumefaciens* virulence (Fig. 3A; Stahl *et al.* 1998). In A348 cells harbouring the RSF1010 derivative pJB31, the T-DNA transfer intermediate accumulates at WT levels, establishing that the IncQ plasmid processing reaction does not disrupt processing by VirD2 relaxase at the T-DNA border sequences (Fig. 3B). In these cells, however, the T-DNA substrate binds VirD4 at only 5–10% of WT levels, indicative of a nearly complete block in substrate-receptor binding (Fig. 3C). In A348 strains harbouring the isogenic IncQ plasmids pAJ1 and pAJ6 bearing mutations in *oriT* and *mobA*, respectively (Stahl *et al.*, 1998), the T-DNA bound VirD4 at WT

levels (Fig. 3C). These findings establish that formation of the MobA-R-strand transfer intermediate is essential for the observed block in T-DNA substrate access to the VirD4 receptor.

Osa blocks T-DNA access to the VirD4 receptor

As mentioned above, the Osa protein encoded by plasmid pSa (IncW) also functions as an oncogenic suppressor (Chen and Kado, 1994; Lee *et al.*, 1999). By use of the mixed infection assay, it was reported that Osa does not inhibit delivery of T-DNA to plant cells (Lee *et al.*, 1999; Lee and Gelvin, 2004). However, in parallel studies in both of our laboratories, we have reproducibly detected strong suppressive effects of Osa on T-DNA transfer upon inoculation of *K. daigremontiana* leaf wounds as well as tobacco leaf discs. As summarized in Fig. 4A and Table 1, A348(pSa) expressing *osa* from its native promoter or A348(pUCD3960) expressing *osa* from an *nptII* promoter displayed highly attenuated virulence. In the mixed infection studies, coinoculation of LBA4404 (Δ T-DNA) with three independently derived *virE2* null mutants [At12516, *virE2::carb* and Mx358 (data not shown)] yielded tumour formation on both *K. daigremontiana* and tobacco leaf discs. In striking contrast, coinoculation of LBA4404 with these *virE2* mutant strains carrying the *osa*-expressing pSa or pUCD3960 plasmids produced no tumours or only a few small tumours. In these assays, the *virE2* mutant strains represent the only source for the oncogenic T-DNA, indicating that the Osa protein at least partially blocks translocation of the T-DNA. Results of our studies examining the effects of Osa on VirE2 translocation are presented below.

By use of the QTrIP assay, we determined that A348(pUCD3960) cells accumulate WT levels of the T-DNA transfer intermediate (Fig. 4B), but appreciably lower amounts of the putative T-DNA substrate–VirD4 receptor complex (Fig. 4C). In this Osa-producing strain, the T-DNA bound the receptor at 30–40% of WT levels (Fig. 4C). Similarly, in this strain the T-DNA substrate bound to VirB11, VirB6, VirB8, VirB2 and VirB9 at 30–40% of WT levels (Fig. 4C and data not shown). It is noteworthy that, in contrast to pML122 (Fig. 3C), Osa does not completely block formation of these T-DNA–channel subunit contacts, yet Osa-producing cells are nearly avirulent (Fig. 4A). Conceivably, Osa disrupts not only the T-DNA–receptor binding reaction, but also interferes with DNA transfer kinetics, a dynamic reaction that cannot be measured with the QTrIP assay. Additionally or alternatively, Osa's strong 'oncogenic suppression' phenotype could be due to its ability to block VirE2 protein substrate binding to the VirD4 receptor (see below).

Overproduction of VirB9, VirB10 and VirB11 does not reverse Osa-mediated oncogenic suppression (Fig. 4A; Lee *et al.* 1999). Correspondingly, VirB9–VirB11 overproduction did not correlate with an increase in T-DNA binding to VirD4 or the VirB channel subunits in the presence of Osa, as shown by QTrIP (Fig. 4C and data not shown). These findings and additional data (see below), suggest that the pML122 transfer intermediate and Osa exert their effects on a common target, the VirD4 receptor, but most probably through different mechanisms.

Previously, we reported that *virE2* fused at its 3' end to the gene for green fluorescent protein (GFP) exerts negative dominance when expressed in A348 cells (Fig. 4A) (Zhou and Christie, 1999). In mixed infection experiments, *virE2-GFP* expression also was reported to suppress both T-DNA and VirE2 translocation (Zhou and Christie, 1999). However, TrIP and QTrIP studies did not reveal any effects of VirE2-GFP on T-DNA binding to the VirD4 receptor or VirB channel subunits (Fig. 4C and data not shown). We also have attempted, without success, to suppress dominance of *virE2-GFP* by overproduction of the VirB/D4 channel subunits, VirE2, or VirE1, a secretion chaperone for VirE2 (Zhao *et al.*, 2001). On the basis of these findings, we suggest that VirE2-GFP acts very early in the translocation pathway, even prior to substrate-receptor docking, to disrupt translocation of VirE2.

The IncQ conjugative intermediate and Osa inhibit VirE2 access to the VirD4 receptor

The RSF1010 transfer intermediate and Osa also block translocation of the VirE2 effector to plant cells (Table 1; Stahl *et al.*, 1998; Lee *et al.*, 1999). We next tested whether these suppressor factors interfere with the VirE2 substrate–VirD4 receptor contact. These studies made use of the bimolecular fluorescence complementation (BiFC) assay (Hu *et al.*, 2002) adapted in our laboratory for *in vivo* studies of the VirE2–VirD4 docking reaction (Atmakuri *et al.*, 2003). In this assay, VirE2 and VirD4 are tagged with half-length GFP molecules, such that the VirE2–VirD4 interaction serves to align the half-GFP's for reconstitution of the active fluorescent protein (Atmakuri *et al.*, 2003). Cells coproducing VirD4-N'GFP and C'GFP–VirE2 fluoresce at the cell poles (Fig. 5A), in agreement with positional information reported previously for VirD4 (Kumar and Das, 2002) and the VirE2–VirD4 complex (Atmakuri *et al.*, 2003). In striking contrast, the isogenic cells carrying pML122 or *osa*-expressing pUCD3960 failed to display any detectable BiFC (Fig. 5A). As shown above for the T-DNA substrate, the suppressor factors similarly block access of the VirE2 protein substrate to the VirD4 receptor.

These findings prompted a cytological test for colocalization of Osa and VirD4. As shown previously, VirD4 and VirD4-GFP localize at *A. tumefaciens* cell poles (Fig. 5B) (Kumar and Das, 2002; Atmakuri *et al.*, 2003). We fused Osa at its C terminus to GFP, and determined that the fusion protein is stable in *A. tumefaciens* and phenotypically resembles the native protein by suppressing virulence, interfering with T-DNA and VirE2 binding to VirD4, and blocking pML122 transfer (data not shown). Very interestingly, Osa-GFP targeted to the *A. tumefaciens* poles, forming fluorescence patterns very similar to those of VirD4-GFP (Fig. 5B). Osa-GFP also targeted to poles of mutant strains deleted of VirD4, the VirB subunits, or the VirD2 relaxase, suggesting that Osa positioning is independent of T-DNA processing or polar localization of the VirB/D4 machine (data not shown). Moreover, native Osa did not affect polar targeting of VirD4-GFP (data not shown), excluding a mechanism whereby Osa interferes with targeting of the receptor to its site of action.

We next assayed for effects of Osa and pML122 on precipitation of a VirD4–VirE2 complex from *A. tumefaciens* cell extracts (Atmakuri *et al.*, 2003). As shown in Fig. 5C, the anti-VirD4 antibodies precipitated abundant levels of VirD4 and VirE2 from extracts of WT A348 cells, but only a barely detectable level of VirE2 from extracts of isogenic strains carrying either pML122 or pUCD3960. These findings comprise further evidence that the suppressor factors act by inhibiting the VirE2–VirD4 binding reaction.

We also asked whether overproduction of the VirD4 receptor could reverse the inhibitory effects of pML122 or Osa. Not surprisingly, elevated receptor synthesis in the VirD4-overproducing strain A348(pKA21) was correlated with a ~5–10% increase in the amount of T-DNA precipitated with anti-VirD4 antibodies as compared with WT A348 cells. However, the QTrIP studies revealed no corresponding increase in T-DNA–VirB channel subunit contacts, in agreement with evidence presented above (Fig. 2) that one or more VirB subunits, not VirD4, is rate-limiting for assembly of the secretory apparatus. The VirD4 antibodies also coprecipitated VirD4 and VirE2 from extracts of A348(pKA21, pML122) (Fig. 5C), establishing that VirD4 overproduction also enabled detection of VirE2-receptor binding in the presence of the IncQ plasmid. In striking contrast, VirD4 overproduction in strain A348 (pKA21, pUCD3960) did not reverse the inhibitory effect of Osa on VirE2–VirD4 complex formation (Fig. 5C). VirD4 overproduction therefore reversed the inhibitory effects of pML122 but not Osa on VirE2–VirD4 receptor binding.

Osa inhibits IncQ plasmid access to the VirD4 receptor

Osa also inhibits conjugative transfer of pML122 to agro-bacterial recipients (Fig. 6A; Lee and Gelvin, 2004). As assessed by QTrIP, Osa interfered with pML122 binding to the VirD4

receptor without further negative effects on substrate binding to the VirB subunits, as illustrated for VirB9 (Fig. 6B and data not shown). The magnitude of the Osa inhibitory effect – approximately 1 log reduction in conjugative transfer frequency and 65% reduction in pML122 binding to the VirD4 receptor as shown by QTrIP – correlate with each other and with the observed effect of Osa on the T-DNA substrate-receptor binding reaction (see Fig. 4B). Also in agreement with data presented above for the T-DNA substrate, VirE2-GFP did not affect pML122 transfer or VirD4 receptor binding (Fig. 6A and B). It is noteworthy that the strains characterized in this study carry two T4S systems in addition to the VirB/D4 T4S system (Hamilton *et al.*, 2000; Chen *et al.*, 2002). However, these T4S machines are not synthesized or functional under conditions required for *vir* gene expression and VirB/D4-mediated translocation, as shown previously and here by lack of detectable pML122 transfer by a PC1000 ($\Delta virB$ operon) donor strain (Fig. 6A; Fullner, 1998; Lee and Gelvin, 2004). Thus, Osa inhibits conjugative transfer of pML122 specifically by interfering with substrate binding to the VirD4 receptor.

The IncQ transfer intermediate and Osa do not affect VirD4-independent, VirB-dependent pCloDF13 transfer

Agrobacterium tumefaciens mobilizes the transfer of another plasmid, pCloDF13, to recipient cells (Escudero *et al.*, 2003). pCloDF13 encodes its own VirD4 homologue, MobB, but lacks genes for the VirB Mpf subunits, and therefore transfer is dependent on assembly of a chimeric T4S system composed of the MobB receptor and VirB channel subunits. To determine whether RSF1010 and Osa act specifically to inhibit VirD4 receptor activity, we assayed for effects of these suppressor factors on pCloDF13 mobilization.

Table 2 shows that WT A348 and the *virD4* null mutant Mx355 transferred the pCloDF13 derivative pJClo (See *Experimental procedures*) to agrobacterial recipients. Mx355 with or without pJClo failed to transfer pML122, showing that VirD4 is required for mobilization of the IncQ plasmid (Table 2; Fullner, 1998). Very interestingly, both A348 and Mx355 donor cells carrying pJClo and either pML122 or pUCD3960 (Osa producer) transferred pJClo at frequencies comparable to cells lacking the oncogenic suppressors. These findings show that the IncQ plasmid and Osa specifically inhibit VirD4 receptor activity without affecting activities of the MobB receptor or the VirB channel subunits.

Discussion

In this study, a combination of biochemical, cytological and genetic findings established that two ‘oncogenic suppressors’ act on a common target, the VirD4 receptor, to block passage of the T-DNA and the VirE2 effector protein through the *A. tumefaciens* VirB/D4 T4S system. One suppressor factor, RSF1010 (IncQ), is a promiscuous plasmid that parasitizes the VirB/D4 system as well as many other T4S systems of Gram-negative bacteria (Rawlings and Tietze, 2001). Studies have shown that TrIP and the semi-quantitative version of this assay permit refined mechanistic studies of T4S machines (Atmakuri *et al.*, 2004; Cascales and Christie, 2004a,b; Jakubowski *et al.*, 2005). Here, by TrIP we provided evidence that the RSF1010 substrate follows the same pathway through the VirB/D4 T4S system as previously shown for the T-DNA (Cascales and Christie, 2004a). Moreover, in strains producing both DNA substrates, the IncQ transfer intermediate formed close contacts with the channel subunits at levels eight to nine times higher than the T-DNA substrate. The copy numbers of RSF1010 and the Ti plasmid in *A. tumefaciens* are estimated at 10–20 and 1–2 respectively (Binns *et al.*, 1995). This correlation between substrate binding and plasmid copy number suggests the RSF1010 substrate accumulates in stoichiometric excess and probably outcompetes the T-DNA for available receptors. By contrast, data presented here and elsewhere (see below) suggest that the second suppressor factor, the Osa protein of pSa (IncW), blocks VirD4 receptor

activity not as a competing substrate but rather through a mechanism shared by related fertility inhibition factors encoded by IncP, W and N conjugative plasmids.

Although we favour a model in which RSF1010 competitively blocks T-DNA access to VirD4, our studies also have supplied evidence that the VirB channel subunits influence receptor activity as well as trafficking through the T4S system. Strikingly, cells engineered to overproduce VirB9, VirB10 and VirB11 displayed a pronounced shift in favour of T-DNA versus RSF1010 binding to VirD4 and the VirB channel subunits (Fig. 2). The VirB overproducing strain might assemble elevated numbers of channel complexes compared with the WT strain, as suggested by an overall increase in levels of substrate binding to channel subunits. However, this slight increase, estimated at approximately 5% by QTrIP, by itself cannot account for the shift in the ratio of T-DNA versus RSF1010 substrate binding. On the basis of these findings, we suggest that overproduction of these VirB proteins preferentially stimulates the VirD4–T-DNA binding reaction. Cells overproducing only one of these subunits, VirB9, VirB10 or VirB11, still display RSF1010 suppression of T-DNA transfer (Ward *et al.*, 1991; data not shown), further indicating that these VirB proteins function together as a subcomplex to modulate receptor activity. Consistent with this view, elsewhere we have presented evidence for a network of VirD4, VirB9, VirB10 and VirB11 interactions in directing substrate translocation across the *A. tumefaciens* cell envelope. Specifically, ATP utilization by VirD4 and VirB11 induces a conformational switch in VirB10 that enables stable complex formation with the outer membrane-associated VirB9. In turn, the T-DNA substrate passes from the inner membrane to the periplasmic and outer membrane portions of the secretion channel (Cascales and Christie, 2004b). Such dynamic interactions between VirB9, VirB10, VirB11 and VirD4 conceivably also regulates early substrate recruitment and receptor binding reactions.

Additional evidence that VirB subunits contribute to substrate selection derives from mutational studies. Small peptide insertions in both VirB9 and VirB11 were shown to confer a substrate discrimination phenotype, such that strains producing the mutant proteins translocate either but not both of the T-DNA or RSF1010 substrates (Sagulenko *et al.*, 2001; Jakubowski *et al.*, 2005; Cascales and Christie, unpublished data). In principle, such mutations could modulate substrate selection through effects on VirD4 receptor activity. However, at least for VirB9 the QTrIP studies instead supplied evidence that the substrate discrimination mutations do not affect the efficiencies of RSF1010 and T-DNA binding to VirD4 or early reactions leading to transfer across the inner membrane. Rather, the mutations selectively block passage of one but not the second DNA substrate through the distal portion of the channel comprised of VirB2 and VirB9. Consequently, VirB9 is postulated to function as a checkpoint to regulate delivery of DNA substrates through the periplasm to the cell surface. Given that these DNA transfer intermediates correspond to the VirD2 and MobA relaxases covalently bound to their respective ssDNA substrates, VirB9 might regulate substrate trafficking through recognition of novel translocation signals carried by the two relaxases (Jakubowski *et al.*, 2005).

Finally, it is noteworthy that RSF1010 also blocks access of the VirE2 effector protein to the VirD4 receptor. This is in spite of the fact that WT *A. tumefaciens* cells synthesize VirE2 in far greater excess than the RSF1010 transfer intermediate (Binns *et al.*, 1995; Zhou and Christie, 1999; Zhao *et al.*, 2001). Conversely, abundant synthesis of native VirE2 or even of VirE2-GFP, a protein that could conceivably jam into the secretion channel due to rapid folding kinetics of GFP, does not affect transfer frequencies of either RSF1010 or T-DNA (Figs 4 and 6; Lee and Gelvin, 2004). These observations strongly suggest that RSF1010 inhibits VirE2 translocation by a mechanism other than simple competitive inhibition. It is also noteworthy that RSF1010 blocks access of both DNA and protein substrates to VirB/D4 channel complexes, whereas native substrates of this T4S system, e.g. T-DNA and VirE2, appear to

have coevolved to minimize competition for available channels. Overall, these observations raise intriguing questions relating to substrate selection by individual VirB/D4 channel complexes. Is a given channel competent to translocation both DNA and protein substrates and, if so, what reactions temporally regulate recruitment and translocation of these substrates? Alternatively, is a channel competent to translocation one type of substrate – DNA or protein – and, if so, what factors govern the biogenesis and function of such dedicated systems? In future studies, it will be of interest to explore mechanistic differences underlying T4S-dependent trafficking of DNA versus protein substrates.

In contrast to RSF1010, pSa-encoded Osa most probably is not a secretion substrate of the VirB/D4 T4S system, as judged by the absence of a characteristic C-terminal translocation signal (Vergunst *et al.*, 2005) and experimental evidence that Osa localizes at the inner membrane (Chen and Kado, 1996). Additionally, Osa does not affect T-DNA substrate processing (Fig. 4), or synthesis or subcellular localization of VirB subunits (Chen and Kado, 1994; 1996). Similar findings for the related FiwA fertility inhibition factor of plasmid RP1 strongly suggest that Osa and FiwA represent a class of plasmid-encoded factors that block trafficking by heterologous T4S systems at a stage subsequent to machine assembly (Olsen and Shipley, 1975; Fong and Stanisich, 1989; Chen and Kado, 1996). Here, we supplied evidence that Osa exerts its effects specifically on the substrate-receptor docking reaction (Fig. 4). The effect of Osa on DNA substrate-receptor binding is less pronounced, however, than that of RSF1010, and general comparisons of QTrIP and virulence data (Cascales and Christie, 2004a; Jakubowski *et al.*, 2005; this study) suggest that this level of inhibition is not sufficient to account for the nearly avirulent phenotype of Osa-producing *A. tumefaciens* cells. Moreover, VirB9, VirB10 and VirB11 overproduction did not reverse Osa-mediated oncogenic suppression or confer elevated levels of T-DNA binding to VirD4 or the VirB channel subunits (Fig. 4). Together, these observations suggest, first, that Osa differs from RSF1010 in its mechanism of action, in agreement with a proposal derived from results of plant infection assays (Lee *et al.*, 1999; Lee and Gelvin, 2004). Second, Osa likely suppresses virulence predominantly by inhibiting the binding of VirE2 and possibly other effector proteins to the VirD4 receptor. Very interestingly, Osa-GFP colocalized with VirD4 at the *A. tumefaciens* poles, constituting the first report of a cell positioning phenotype for a plasmid fertility inhibition factor. Yet, Osa targeting proceeds independently of VirD4 or the VirB channel subunits, and even occurs in a strain deleted of the Ti plasmid. Additionally, we have been unable to gain biochemical or two-hybrid evidence for complex formation between Osa and VirD4 (data not shown). Therefore, while enticing it remains a working model that Osa exerts its effects by modulating VirD4 receptor activity through a direct protein–protein interaction.

To complement our biochemical studies, we exploited a genetic screen originally devised in a characterization of the FipA and PifC fertility inhibition factors of plasmids pKM101 and F respectively (Santini and Stanisich, 1998). In that study, FipA and PifC were shown to block transfer of IncP α plasmid RP1 (equivalent to RP4) as well as RSF1010 through the RP1-encoded T4S system, but not the transfer of pCloDF13 by cells carrying a RP1 *traG* mutant. pCloDF13 encodes its own MobB receptor, which interacts with the RP1 Mpf proteins to yield a functional, chimeric T4S system. This specificity of PifC and FipA for RP1 TraG and not for pCloDF13 MobB constituted early genetic evidence that these factors inhibit plasmid transfer via effects on the RP1 TraG receptor (Santini and Stanisich, 1998). Similarly, we determined that Osa inhibits VirD4 but not CloDF13 MobB receptor activities. Thus, a combination of genetic, cytological, and biochemical findings (Santini and Stanisich, 1998; this study) strongly support a general proposal that a class of fertility inhibition factors represented by Osa (IncW), PifC (IncF), FipA (IncN) and FiwA (IncP) exert their effects by interfering with substrate docking at cognate VirD4/TraG-like receptors. The ability of MobB to interface with various T4S systems, together with its apparent immunity to inhibition factors,

makes this an intriguing receptor for future structure–function studies exploring molecular details of substrate–receptor and receptor–Mpf channel subunit contacts.

The strong blocking action by Osa on an effector protein–T4S receptor binding reaction is of special interest because, as noted above, plasmid fertility inhibition has been considered a mechanism for preventing translocation of coresident plasmids. With a revised view that such factors also inhibit protein substrate trafficking through T4S systems, it is tempting to suggest that Osa or molecular mimics will prove effective in suppressing virulence of medically significant pathogens, e.g. *Helicobacter pylori*, *Legionella pneumophila*, and *Bartonella* and *Burkholderia* spp. whose infection cycles are dependent on T4S-mediated protein translocation (Segal and Shuman, 1998; Vogel *et al.*, 1998; Cascales and Christie, 2003; Dehio, 2005). Additionally, there is increasing evidence that conjugation systems translocate protein substrates independently of DNA to bacterial recipients (Wilkins and Thomas, 2000; Luo and Isberg, 2004). Studies with fertility inhibition factors also should prove useful in evaluating the extent to which T4S-mediated protein trafficking represents a source of information flow in bacterial communities.

Experimental procedures

Strains, growth conditions and plasmids

Agrobacterium tumefaciens A348 is strain C58 bearing the octopine-type pTiA6NC plasmid (Zhu *et al.*, 2000). A348 derivatives include Mx358 (*virE2*), Mx355 (*virD4*) (Stachel and Nester, 1986), At12516 (*virE2*) (Fullner *et al.*, 1996), PC1000 (Δ *virB* operon) (Fernandez *et al.*, 1996) and LBA4404 (Δ T-DNA) (Ooms *et al.*, 1982). C58C1RS (C58, Str^r, Rif^r) (Van Larebeke *et al.*, 1975) and the Ti-plasmid-less strain UIA143 (C58 *recA*, Ery^r) (Farrand *et al.*, 1989) were used for conjugation experiments. Strain KA2000 (A348 Δ *virD4*) was constructed by deletion of the *virD4* gene in *A. tumefaciens* strain A348 by marker exchange-eviction mutagenesis (Berger and Christie, 1993) using plasmid pKA126 (Atmakuri *et al.*, 2004).

Agrobacterium tumefaciens strains were grown in Luria–Bertani (LB) supplemented with mannitol and glutamate at 28°C (Zhou and Christie, 1999). Conditions for induction of the *A. tumefaciens* *vir* genes in AB inducing medium [ABIM, glucose-containing minimal medium (pH 5.5), 1 mM phosphate, 200 μ M acetosyringone (AS)] have been described previously (Zhou and Christie, 1999). When necessary, medium was supplemented with antibiotics (in μ g ml⁻¹) as follows: gentamicin (100), kanamycin (100), tetracycline (5), carbenicillin (100 or 5 for strain LBA4404), spectinomycin (500), rifampicin (75), erythromycin (100), streptomycin (100).

RSF1010 plasmid derivatives used in this study are: pML122 (Gen^r, Kan^r) and pML122 Δ Kan (Gen^r) (Fullner, 1998), pJB31 (Spc^r) (Beaupre *et al.*, 1997), pAJ1 (pJB31 *mobA*) and pAJ6 (pJB31 *oriT*) (Stahl *et al.*, 1998). Additional plasmids include pSa (*osa* expressed from native promoter), pUCD3960 (Spc^r, Crb^r; *osa* constitutively expressed from *nptI* promoter) (Chen and Kado, 1994), pXZ66 (Kan^r, P_{*virB*}-*virE2-gfp*) (Zhou and Christie, 1999), pED9 (Tet^r, P_{*virB*}-*virB9-10-11*) (Ward *et al.*, 1990), pJClo, a pBin19 derivative carrying the *mob* region of pCloDF13 (Kan^r; gift from J. Escudero, A. Vergunst and P. J. J. Hooykaas) (Nijkamp *et al.*, 1986), pBSBBR (Crb^r, Kan^r) constructed by ligation of pBluescript plasmid (Crb^r) with the broad host range vector pBBR1MCS2 (Kan^r) (Kovach *et al.*, 1994), the IncP derivative pKA21 (P_{*virB*}-*virD4*) (Atmakuri *et al.*, 2003), and ColE1 plasmids pKA64 (P_{*virB*}-*virD4*-N'GFP) and pKV38 (P_{*virB*}-GFP'C-*virE2*) (Atmakuri *et al.*, 2003), respectively, ligated into the broad host range plasmids pBBRMCS-General (Gen^r) (Kovach *et al.*, 1994) and pSW172 (Tet^r) (Chen and Winans, 1991).

The *osa* gene was PCR-amplified with primers 5'-GCGCTAACGATGCATATGTTGCTACGGCGG-3' and 5'-AAAGCGCAGGGACTCGAGTCACTATTCTAGAATCTTCCT GCATTG-3' and pUCD3960 (Lee *et al.*, 1999) as a template. Amplified DNA was cloned as a 0.57-kb NdeI/XhoI fragment into corresponding sites of pPC914KS⁺ (Berger and Christie, 1994) to obtain pKA165, which expresses *P_{virB}-osa*. *Osa* fused at its C terminus to GFP was constructed as follows. The MCS upstream of the *virB* promoter was destroyed by digesting pKA165 with SacII/EcoRV, blunt-ending and religating to obtain pKA166. A 0.73-kb XbaI/KpnI fragment containing *GFP* from pXZ63 (Rashkova *et al.*, 2000) was ligated into the corresponding sites of pKA166 to obtain pKA167, which expresses *P_{virB}-osa-gfp*.

Virulence and extracellular complementation assays

Kalanchoe leaf assay. *Agrobacterium tumefaciens* strains were tested for virulence by inoculating wound sites of *K. daigremontiana* leaves as previously described (Berger and Christie, 1994). For extracellular complementation experiments, 0.5 ml of both strains at a similar optical density (OD₆₀₀~0.8) were mixed in an Eppendorf tube and centrifuged. The pellet was resuspended in 100 µl and 25 µl was used to inoculate wounded *K. daigremontiana* leaves. WT A348 and avirulent mutant strains served as controls for the tumorigenesis assay. Virulence of strains or mixed infections was assayed at least three times on separate leaves.

Tobacco leaf square assay. Pieces (4 mm²) from surface sterilized mature young vegetative leaves of *Nicotiana tabacum* cv H425 plants were briefly soaked in a bacterial culture in LB (OD₆₀₀~0.5) and then placed onto MS basal media plates supplemented with 300 µM AS. After 2 days at 25°C in the dark, pieces were washed with LB medium containing timentin (200 µg ml⁻¹) and vancomycin (200 µg ml⁻¹). Pieces were then placed onto MS basal medium plates supplemented with timentin and vancomycin. After 10 days at 25°C in the dark, tumours arising along the edges of each piece were counted. In each experiment, 16 leaf pieces were tested per bacterial strain (or mix) and each experiment was repeated in triplicate.

Conjugation assays

Agrobacterium tumefaciens donor strains carrying the RSF1010 derivative pML122ΔKm were mated with recipient strains A348 or At12516 (*virE2*⁻) carrying plasmid pBBR1MCS (Str^r). Briefly, mid-log phase (OD₆₀₀~0.4) cells grown in MG1⁻¹ broth were harvested and incubated in ABIM for 8 h at 22°C to induce *vir* gene expression. Cells were adjusted to an OD₆₀₀~0.5, mixed in a donor to recipient ratio of 1 to 5 and spotted onto a nitrocellulose filter placed on an ABIM agar plate. *A. tumefaciens* donor cells carrying pJClo and UIA143 (Ery^r) recipient cells were mixed in a ratio of 1 to 25 before inoculation on filter discs. The mating mixtures were incubated for 4 days at 18°C. Cells were recovered from the filters, serially diluted, and plated onto MG1 medium selective for transconjugant or donor cells. Frequencies of transfer were estimated as transconjugants recovered per donor. Experiments were repeated three times and results are reported for a representative experiment.

Coimmunoprecipitation

Coimmunoprecipitation was performed as described previously (Atmakuri *et al.*, 2003). Briefly, 500 ml of induced *A. tumefaciens* cultures were harvested and cells were lysed by French press treatment. Total membranes were recovered by ultracentrifugation, cross-linked with 0.5 mg ml⁻¹ of dithiobis(succidimidyl propionate; DSP), and solubilized with 1.5% N-Lauoryl sarcosine. The solubilized membranes were used as starting material for immunoprecipitation with anti-VirD4 antibodies coupled to Protein A-Sepharose CL-4B beads (Amersham Biosciences).

Bimolecular fluorescence complementation interaction assay

The BiFC assay was carried out as previously described (Atmakuri *et al.*, 2003). Freshly transformed *A. tumefaciens* cells were incubated in ABIM and examined between 6 and 16 h post induction by fluorescence microscopy using an Olympus BX60 microscope equipped with a 100× oil immersion phase-contrast objective (Ding *et al.*, 2002).

Transfer DNA ImmunoPrecipitation

Transfer DNA ImmunoPrecipitation and semi-quantitative TrIP (QTrIP) were carried out as previously described (Cascales and Christie, 2003). Primers for amplification were: 5'-GGGCGATTATGGCATCCAGAAAGCC and 5'-GTCCGGC GGCCCACTTGGCACACAG for gene 7 present on the T_L-DNA, 5'-CCTGCGGATGTACAGGGCTCTCGT and 5'-TGTC CGTGCTTGCCAATCCCCG for the *ophDC* locus on pTiA6NC (control), 5'-CTCAGTGGTTCAAGCGGTACA and 5'-TGATAGTTCTTCGGGCTGGTT for a fragment of *mobA* carried on RSF1010 derivatives used in this study, and 5'-GTGAGCAAAGCCGCTGCC and 5'-AGCCAATTGATCCT GCA for a fragment of the *repAB* loci on pTiAch5 (control).

Acknowledgments

The authors thank Lan-Ying Lee and Stan Gelvin for plasmids pUCD3960 and pSa and for helpful discussions, and members of the Christie and Binns labs for helpful discussions. We also thank J. Escudero, A. Vergunst and P. J. J. Hooykaas for the gift of pJClo. We thank S. Farrand for the gift of strain C58C1RS. We thank the Margolin lab for use of their microscopy facility. This study was supported by NIH Grant GM48746 to P.J.C. and NSF MCB0421885 to A.N.B.

References

- Atmakuri K, Ding Z, Christie PJ. VirE2, a type IV secretion substrate, interacts with the VirD4 transfer protein at cell poles of *Agrobacterium tumefaciens*. *Mol Microbiol* 2003;49:1699–1713. [PubMed: 12950931]
- Atmakuri K, Cascales E, Christie PJ. Energetic components VirD4, VirB11 and VirB4 mediate early DNA transfer reactions required for bacterial type IV secretion. *Mol Microbiol* 2004;54:1199–1211. [PubMed: 15554962]
- Beaupre CE, Bohne J, Dale EM, Binns AN. Interactions between VirB9 and VirB10 membrane proteins involved in movement of DNA from *Agrobacterium tumefaciens* into plant cells. *J Bacteriol* 1997;179:78–89. [PubMed: 8981983]
- Beranek A, Zettl M, Lorenzoni K, Schauer A, Manhart M, Koraimann G. Thirty-eight C-terminal amino acids of the coupling protein TraD of the F-like conjugative resistance plasmid R1 are required and sufficient to confer binding to the substrate selector protein TraM. *J Bacteriol* 2004;186:6999–7006. [PubMed: 15466052]
- Berger BR, Christie PJ. The *Agrobacterium tumefaciens virB4* gene product is an essential virulence protein requiring an intact nucleoside triphosphate-binding domain. *J Bacteriol* 1993;175:1723–1734. [PubMed: 8449880]
- Berger BR, Christie PJ. Genetic complementation analysis of the *Agrobacterium tumefaciens virB* operon: *virB2* through *virB11* are essential virulence genes. *J Bacteriol* 1994;176:3646–3660. [PubMed: 8206843]
- van Biesen T, Frost LS. The FinO protein of IncF plasmids binds FinP antisense RNA and its target, *traJ* mRNA, and promotes duplex formation. *Mol Microbiol* 1994;14:427–436. [PubMed: 7533880]
- Binns A, Beaupre C, Dale E. Inhibition of VirB-mediated transfer of diverse substrates from *Agrobacterium tumefaciens* by the IncQ plasmid RSF1010. *J Bacteriol* 1995;177:4890–4899. [PubMed: 7665465]
- Buchanan-Wollaston V, Passiatore JE, Cannon F. The *mob* and *oriT* mobilization functions of a bacterial plasmid promote its transfer to plants. *Nature* 1987;328:172–175.

- Cascales E, Christie PJ. The versatile bacterial type IV secretion systems. *Nat Rev Microbiol* 2003;1:137–150. [PubMed: 15035043]
- Cascales E, Christie PJ. Definition of a bacterial type IV secretion pathway for a DNA substrate. *Science* 2004a;304:1170–1173. [PubMed: 15155952]
- Cascales E, Christie PJ. *Agrobacterium* VirB10, an ATP energy sensor required for type IV secretion. *Proc Natl Acad Sci USA* 2004b;101:17228–17233. [PubMed: 15569944]
- Chen CY, Winans SC. Controlled expression of the transcriptional activator gene *virG*. *Agrobacterium tumefaciens* by using the *Escherichia coli lac* promoter. *J Bacteriol* 1991;173:1139–1144. [PubMed: 1991713]
- Chen CY, Kado CI. Inhibition of *Agrobacterium tumefaciens* oncogenicity by the *osa* gene of pSa. *J Bacteriol* 1994;176:5697–5703. [PubMed: 8083162]
- Chen CY, Kado CI. Osa protein encoded by plasmid pSa is located at the inner membrane but does not inhibit membrane association of VirB and VirD virulence proteins in *Agrobacterium tumefaciens*. *FEMS Microbiol Lett* 1996;135:85–92. [PubMed: 8598281]
- Chen L, Chen Y, Wood DW, Nester EW. A new type IV secretion system promotes conjugative transfer in *Agrobacterium tumefaciens*. *J Bacteriol* 2002;184:4838–4845. [PubMed: 12169609]
- Christie PJ, Cascales E. Structural and dynamic properties of bacterial type IV secretion [Review]. *Mol Membr Biol* 2005;22:51–61. [PubMed: 16092524]
- Christie PJ, Ward JE, Winans SC, Nester EW. The *Agrobacterium tumefaciens virE2* gene product is a single-stranded-DNA-binding protein that associates with T-DNA. *J Bacteriol* 1988;170:2659–2667. [PubMed: 2836366]
- Close SM, Kado CI. The *osa* gene of pSa encodes a 21.1-kilodalton protein that suppresses *Agrobacterium tumefaciens* oncogenicity. *J Bacteriol* 1991;173:5449–5456. [PubMed: 1832152]
- Dehio C. *Bartonella*-host-cell interactions and vascular tumour formation. *Nat Rev Microbiol* 2005;3:621–631. [PubMed: 16064054]
- Ding Z, Zhao Z, Jakubowski SJ, Krishnamohan A, Margolin W, Christie PJ. A novel cytology-based, two-hybrid screen for bacteria applied to protein–protein interaction studies of a type IV secretion system. *J Bacteriol* 2002;184:5572–5582. [PubMed: 12270814]
- Ding Z, Atmakuri K, Christie PJ. The outs and ins of bacterial type IV secretion substrates. *Trends Microbiol* 2003;11:527–535. [PubMed: 14607070]
- Escudero J, Den Dulk-Ras A, Regensburg-Tuink TJ, Hooykaas PJ. VirD4-independent transformation by CloDF13 evidences an unknown factor required for the genetic colonization of plants via *Agrobacterium*. *Mol Microbiol* 2003;47:891–901. [PubMed: 12581347]
- Farrand SK, O'Morchoe SP, McCutchan J. Construction of an *Agrobacterium tumefaciens* C58 *recA* mutant. *J Bacteriol* 1989;171:5314–5321. [PubMed: 2676971]
- Fernandez D, Spudich GM, Zhou XR, Christie PJ. The *Agrobacterium tumefaciens* VirB7 lipoprotein is required for stabilization of VirB proteins during assembly of the T-complex transport apparatus. *J Bacteriol* 1996;178:3168–3176. [PubMed: 8655495]
- Fong ST, Stanisich VA. Location and characterization of two functions on RP1 that inhibit the fertility of the IncW plasmid R388. *J Gen Microbiol* 1989;135:499–502. [PubMed: 2559940]
- Fullner KJ. Role of *Agrobacterium virB* genes in transfer of T complexes and RSF1010. *J Bacteriol* 1998;180:430–434. [PubMed: 9440537]
- Fullner KJ, Lara JC, Nester EW. Pilus assembly by *Agrobacterium* T-DNA transfer genes. *Science* 1996;273:1107–1109. [PubMed: 8688097]
- Gasson M, Willetts N. Transfer gene expression during fertility inhibition of the *Escherichia coli* K12 sex factor F by the I-like plasmid R62. *Mol Gen Genet* 1976;149:329–333. [PubMed: 799252]
- Ghetu AF, Gubbins MJ, Frost LS, Glover JN. Crystal structure of the bacterial conjugation repressor finO. *Nat Struct Biol* 2000;7:565–569. [PubMed: 10876242]
- Gomis-Ruth FX, Sola M, de la Cruz F, Coll M. Coupling factors in macromolecular type-IV secretion machineries. *Curr Pharm Des* 2004;10:1551–1565. [PubMed: 15134575]
- Hamilton CM, Lee H, Li PL, Cook DM, Piper KR, von Bodman SB, et al. TraG from RP4 and TraG and VirD4 from Ti plasmids confer relaxosome specificity to the conjugative transfer system of pTiC58. *J Bacteriol* 2000;182:1541–1548. [PubMed: 10692358]

- Hu CD, Chinenov Y, Kerppola TK. Visualization of interactions among bZIP and Rel family proteins in living cells using bimolecular fluorescence complementation. *Mol Cell* 2002;9:789–798. [PubMed: 11983170]
- Jakubowski SJ, Cascales E, Krishnamoorthy V, Christie PJ. *Agrobacterium tumefaciens* VirB9, an outer-membrane-associated component of a type IV secretion system, regulates substrate selection and T-pilus biogenesis. *J Bacteriol* 2005;187:3486–3495. [PubMed: 15866936]
- Kovach ME, Phillips RW, Elzer PH, Roop RM 2nd, Peterson KM. pBBR1MCS: a broad-host-range cloning vector. *Biotechniques* 1994;16:800–802. [PubMed: 8068328]
- Kumar RB, Das A. Polar location and functional domains of the *Agrobacterium tumefaciens* DNA transfer protein VirD4. *Mol Microbiol* 2002;43:1523–1532. [PubMed: 11952902]
- Lawley, T.; Wilkins, BM.; Frost, LS. Bacterial conjugation in Gram-negative bacteria. In: Funnell, BE.; Phillips, GJ., editors. *Plasmid Biology*. Washington, DC: American Society for Microbiology Press; 2004. p. 203-226.
- Lee LY, Gelvin SB. Osa protein constitutes a strong oncogenic suppression system that can block *vir*-dependent transfer of IncQ plasmids between *Agrobacterium* cells and the establishment of IncQ plasmids in plant cells. *J Bacteriol* 2004;186:7254–7261. [PubMed: 15489437]
- Lee LY, Gelvin SB, Kado CI. pSa causes oncogenic suppression of *Agrobacterium* by inhibiting VirE2 protein translocation. *J Bacteriol* 1999;181:186–196. [PubMed: 9864329]
- Lessl M, Lanka E. Common mechanisms in bacterial conjugation and Ti-mediated T-DNA transfer to plant cells. *Cell* 1994;77:321–324. [PubMed: 8181052]
- Lessl M, Balzer D, Weyrauch K, Lanka E. The mating pair formation system of plasmid RP4 defined by RSF1010 mobilization and donor-specific phage propagation. *J Bacteriol* 1993;175:6415–6425. [PubMed: 8407818]
- Llosa M, Zunzunegui S, De la Cruz F. Conjugative coupling proteins interact with cognate and heterologous VirB10-like proteins while exhibiting specificity for cognate relaxosomes. *Proc Natl Acad Sci USA* 2003;100:10465–10470. [PubMed: 12925737]
- Luo ZQ, Isberg RR. Multiple substrates of the *Legionella pneumophila* Dot/Icm system identified by inter-bacterial protein transfer. *Proc Natl Acad Sci USA* 2004;101:841–846. [PubMed: 14715899]
- Nijkamp HJ, de Lang R, Stuitje AR, van den Elzen PJ, Veltkamp E, van Putten AJ. The complete nucleotide sequence of the bacteriocinogenic plasmid CloDF13. *Plasmid* 1986;16:135–160. [PubMed: 3749334]
- Olsen RH, Shipley PL. RP1 properties and fertility inhibition among P, N, W, and X incompatibility group plasmids. *J Bacteriol* 1975;123:28–35. [PubMed: 1095558]
- Ooms G, Hooykaas PJJ, Van Veen RJM, Van Beelen P, Regensburg-Tunik R, Schilperoort RA. Octopine Ti-plasmid deletion mutants of *Agrobacterium tumefaciens* with emphasis on the right side of the T-region. *Plasmid* 1982;7:15–19. [PubMed: 6283573]
- Otten L, De Greve H, Leemans J, Hain R, Hooykaas P, Schell J. Restoration of virulence of *vir* region mutants of *Agrobacterium tumefaciens* strain B6S3 by coinfection with normal and mutant *Agrobacterium* strains. *Mol Gen Genet* 1984;195:159–163.
- Pansegrau W, Lanka E. Enzymology of DNA transfer by conjugative mechanisms. *Progr Nucleic Acid Res Mol Biol* 1996;54:197–251.
- Pantoja M, Chen L, Chen Y, Nester EW. *Agrobacterium* type IV secretion is a two-step process in which translocation substrates associate with the virulence protein VirJ in the periplasm. *Mol Microbiol* 2002;45:1325–1335. [PubMed: 12207700]
- Penfold SS, Simon J, Frost LS. Regulation of the expression of the *traM* gene of the F sex factor of *Escherichia coli*. *Mol Microbiol* 1996;20:549–558. [PubMed: 8736534]
- Rashkova S, Zhou XR, Christie PJ. Self-assembly of the *Agrobacterium tumefaciens* VirB11 traffic ATPase. *J Bacteriol* 2000;182:4137–4145. [PubMed: 10894719]
- Rawlings DE, Tietze E. Comparative biology of IncQ and IncQ-like plasmids. *Microbiol Mol Biol Rev* 2001;65:481–496. [PubMed: 11729261]
- Sagulenko Y, Sagulenko V, Chen J, Christie PJ. Role of *Agrobacterium* VirB11 ATPase in T-pilus assembly and substrate selection. *J Bacteriol* 2001;183:5813–5825. [PubMed: 11566978]
- Santini JM, Stanisich VA. Both the *fipA* gene of pKM101 and the *pifC* gene of F inhibit conjugative transfer of RP1 by an effect on TraG. *J Bacteriol* 1998;180:4093–4101. [PubMed: 9696755]

- Schrammeijer B, Dulk-Ras Ad A, Vergunst AC, Jurado Jacome E, Hooykaas PJ. Analysis of Vir protein translocation from *Agrobacterium tumefaciens* using *Saccharomyces cerevisiae* as a model: evidence for transport of a novel effector protein VirE3. *Nucleic Acids Res* 2003;31:860–868. [PubMed: 12560481]
- Shroder G, Lanka E. The mating pair formation system of conjugative plasmids – A versatile secretion machinery for transfer of proteins and DNA. *Plasmid* 2005;54:1–25. [PubMed: 15907535]
- Schroder G, Krause J, Zechner EL, Traxler B, Yeo HJ, Lurz R, et al. TraG-like proteins of DNA transfer systems and of the *Helicobacter pylori* type IV secretion system: inner membrane gate for translocated substrates? *J Bacteriol* 2002;184:2767–2779. [PubMed: 11976307]
- Segal G, Shuman HA. Intracellular multiplication and human macrophage killing by *Legionella pneumophila* are inhibited by conjugative components of IncQ plasmid RSF1010. *Mol Microbiol* 1998;30:197–208. [PubMed: 9786196]
- Simone M, McCullen CA, Stahl LE, Binns AN. The carboxy-terminus of VirE2 from *Agrobacterium tumefaciens* is required for its transport to host cells by the *virB*-encoded type IV transport system. *Mol Microbiol* 2001;41:1283–1293. [PubMed: 11580834]
- Stachel SE, Nester EW. The genetic and transcriptional organization of the *vir* region of the A6 Ti. *EMBO J* 1986;5:1445–1454. [PubMed: 3017694]
- Stahl LE, Jacobs A, Binns AN. The conjugative intermediate of plasmid RSF1010 inhibits *Agrobacterium tumefaciens* virulence and VirB-dependent translocation of VirE2. *J Bacteriol* 1998;180:3933–3939. [PubMed: 9683491]
- Tanimoto K, Iino T. Transfer inhibition of RP4 by F factor. *Mol Gen Genet* 1983;192:104–109. [PubMed: 6139738]
- Van Larebeke N, Genetello C, Schell J, Schilperoort RA, Hermans AK, Van Montagu M, Hernalsteens JP. Acquisition of tumour-inducing ability by non-oncogenic agrobacteria as a result of plasmid transfer. *Nature* 1975;255:742–743. [PubMed: 1134573]
- Vergunst AC, Schrammeijer B, den Dulk-Ras A, de Vlaam CM, Regensburg-Tuink TJ, Hooykaas PJ. VirB/D4-dependent protein translocation from *Agrobacterium* into plant cells. *Science* 2000;290:979–982. [PubMed: 11062129]
- Vergunst AC, van Lier MC, den Dulk-Ras A, Grosse Stuve TA, Ouwehand A, Hooykaas PJ. Positive charge is an important feature of the C-terminal transport signal of the VirB/D4-translocated proteins of *Agrobacterium*. *Proc Natl Acad Sci USA* 2005;102:832–837. [PubMed: 15644442]
- Vogel JP, Andrew HL, Wong SK, Isberg RR. Conjugative transfer by the virulence system of *Legionella pneumophila*. *Science* 1998;279:873–876. [PubMed: 9452389]
- Ward JE, Dale EM, Christie PJ, Nester EW, Binns AN. Complementation analysis of *Agrobacterium tumefaciens* Ti plasmid *virB* genes by use of a *vir* promoter expression vector: *virB9*, *virB10*, and *virB11* are essential virulence genes. *J Bacteriol* 1990;172:5187–5199. [PubMed: 2203743]
- Ward JE, Dale EM, Binns AN. Activity of the *Agrobacterium* T-DNA transfer machinery is affected by *virB* genes products. *Proc Natl Acad Sci USA* 1991;88:9350–9354. [PubMed: 11607226]
- Wilkins BM, Thomas AT. DNA-independent transport of plasmid primase protein between bacteria by the II conjugation system. *Mol Microbiol* 2000;38:650–657. [PubMed: 11069687]
- Winans SC, Walker GC. Fertility inhibition of RP1 by IncN plasmid pKM101. *J Bacteriol* 1985;161:425–427. [PubMed: 2857164]
- Yusoff K, Stanisich VA. Location of a function on RP1 that fertility inhibits Inc W plasmids. *Plasmid* 1984;11:178–181. [PubMed: 6374705]
- Zhao Z, Sagulenko E, Ding Z, Christie PJ. Activities of *virE1* and the VirE1 secretion chaperone in translocation of the multifunctional VirE2 effector via an *Agrobacterium* type IV secretion pathway. *J Bacteriol* 2001;183:3855–3865. [PubMed: 11395448]
- Zhou XR, Christie PJ. Mutagenesis of *Agrobacterium* VirE2 single-stranded DNA-binding protein identifies regions required for self association and interaction with VirE1 and a permissive site for hybrid protein construction. *J Bacteriol* 1999;181:4342–4352. [PubMed: 10400593]
- Zhu J, Oger PM, Schrammeijer B, Hooykaas PJ, Farrand SK, Winans SC. The bases of crown gall tumorigenesis. *J Bacteriol* 2000;182:3885–3895. [PubMed: 10869063]




Fig. 1. An RSF1010 derivative forms close contacts with six VirB/D4 subunits during translocation. Strain LBA4404 (Δ T-DNA) with or without pML122 was assayed for formation of pML122 contacts with VirB/D4 channel subunits by TrIP

A. Control experiment showing PCR amplification of pTiAch5 *repAB* (Ct) and pML122 *mobA* (IncQ) fragments in the soluble fraction (S) but not material immunoprecipitated (IP) with anti-VirD2 antibodies from LBA4404 extracts.

B and C. Antibodies to the VirD4 receptor (panel B) and the VirB/VirJ subunits listed on the left (panel C) were used to immunoprecipitate material from extracts of FA-treated LBA4404 and LBA4404(pML122) cells. Both the *repAB* control (Ct) and pML122 *mobA* (IncQ) fragments were detected in solubilized material (S) by PCR amplification. The *mobA* fragment was detected only in the material precipitated with antibodies to VirD4, VirB2, VirB6, VirB8, VirB9 and VirB11.




Fig. 2. The pML122 IncQ plasmid substrate blocks formation of T-DNA close contacts with VirB/D4 channel subunits

A. Inoculated *Kalanchoe daigremontiana* leaves were scored for tumour formation on a scale of no tumours (-) to WT tumours (+++) 5 weeks after inoculation with WT A348, A348 (pML122), or A348(pML122, pED9). The latter strain overproduces VirB9, VirB10 and VirB11 from an IncP replicon.

B. Effects of pML122 and VirB9, VirB10 and VirB11 overproduction on formation of the T-DNA transfer intermediate. Antibodies to VirD2 relaxase precipitated equivalent amounts of the T-DNA substrate from extracts of A348 strains listed in A, as shown by TrIP (bottom) and QTrIP (top). TrIP: The *ophDC* control (Ct), pML122 *mobA* (IncQ) and gene 7 (T-DNA) fragments were detected by PCR amplification from soluble fractions (S) and

immunoprecipitates (IP) of A348, A348(pML122) and A348(pML122, pED9). QTrIP: Levels of processed T-DNA (T-strand) in the immunoprecipitates were quantitated as described previously (Cascales and Christie, 2004a). Results are presented as a fraction of the T-DNA detected in the immunoprecipitates from WT A348 (normalized to 1.0).

C. Antibodies to the VirD4 receptor and the five putative VirB channel subunits presented at the left of each TrIP panel were used to immunoprecipitate material from extracts of strains listed in A. TrIP: Detection of PCR amplification products corresponding to *ophDC* (Ct), pML122 and T-DNA fragments from soluble fractions (S) and immunoprecipitates (IP) recovered from the three strains listed in A. QTrIP: Levels of processed T-DNA (middle histograms) and pML122 (top histograms) in the immunoprecipitates, presented as described in B.




Fig. 3. The *IncQ* plasmid transfer intermediate inhibits T-DNA transfer

A. *Kalanchoe daigremontiana* leaves were scored for tumour formation on a scale of no tumours (-) to WT tumours (+++) 5 weeks after inoculation with WT A348 strain carrying RSF1010 plasmid pJB31 or the isogenic derivative plasmids pAJ1 (*mobA*) or pAJ6 (*oriT*), or control plasmid pBS-BBR.

B. Effects of the *IncQ* plasmid and derivatives on T-DNA processing, as monitored by precipitation of the VirD2-T-strand substrate with antibodies to VirD2 from extracts of the strains listed in A. Bottom: TrIP data showing amplification of *ophDC* (Ct), pML122 *mobA* (*IncQ*) and gene 7 (T-DNA) fragments from soluble fractions (S) and immunoprecipitates (IP). DNA size markers (kb) are at the left. Top: QTrIP data showing levels of T-DNA recovered from the various strains as a fraction of T-DNA substrate from WT A348 (normalized to 1.0).

C. Effects of the *IncQ* plasmid and derivatives on T-DNA transfer. Lower panel: TrIP data showing amplification of pTiAch5 *repAB* (Ct), pML122 *mobA* (*IncQ*) or T-DNA. DNA size markers (kb) are at the left. Upper panel: QTrIP data showing levels of T-DNA in the immunoprecipitates recovered with antibodies to VirD4 (left panels) and VirB9 (right panels).




Fig. 4. The pSa Osa protein blocks VirD4 receptor access to the T-DNA

A. *Kalanchoe daigremontiana* leaves were scored for tumour formation on a scale of no tumours (-) to WT tumours (+++) 5 weeks after inoculation with WT A348, or A348 derivatives producing Osa from plasmid pUCD3960 (Osa) or VirE2-GFP (E2-GFP) from plasmid pXZ66, or overproducing VirB9, VirB10 and VirB11 from pED9.

B. Effects of Osa and VirE2-GFP production on T-DNA processing, as monitored by precipitation of the T-DNA substrate with antibodies to VirD2 from extracts of the strains listed in A. For the QTrIP data presented in the upper histogram, the amounts of T-DNA recovered from the various strains are presented as a fraction of T-DNA recovered from WT A348 (normalized to 1.0).

C. Effects of Osa and VirE2-GFP production on T-DNA transfer. Lower panels: TrIP data showing amplification of *ophDC* (Ct) and gene 7 (T-DNA) fragments from soluble fractions (S) and immunoprecipitates (IP) with antibodies to VirD4 (left) or VirB9 (right). Upper panels: QTrIP data showing levels of T-DNA recovered from the various strains.




Fig. 5. The IncQ plasmid substrate and Osa disrupt VirE2 substrate–VirD4 receptor binding
A. A348 strains coproduced VirD4-N'-GFP and GFP'C-VirE2 from plasmids pKA64 and pZD89, respectively, and harboured pML122 (IncQ plasmid) or pUCD3960 for Osa production as denoted at the left. Cells were examined at 12 h after *vir* gene induction by Nomarski (DIC) microscopy and fluorescence (Fluor) microscopy for detection of bimolecular fluorescence complementation (BiFC). Number to the right of each panel represents the percentage of cells with polar fluorescence among 10^4 cells examined.
B. Colocalization of Osa-GFP and VirD4-GFP at the cell poles. A348 (WT) cells producing Osa-GFP from pKA167 (this study) or VirD4-GFP from pKA62 (Atmakuri *et al.*, 2003) were photographed 12 h after *vir* gene induction by Nomarski (DIC) and fluorescence (Fluor) microscopy. Number to the right of each panel represents the percentage of cells with polar fluorescence among 10^4 cells examined.
C. Coimmunoprecipitation of VirE2–VirD4. Isolated membranes were cross-linked with DSP and detergent-solubilized complexes were subjected to immunoprecipitation with antibodies

to VirD4. Immunoblots were developed with antibodies listed at the right of the top two panels. Strains: Mx355 (*virD4*), At12516 (*virE2*), WT A348 (-), A348(D4) VirD4 is overproduced from pKA21. The latter strains also harboured pML122 (IncQ plasmid) or pUCD3960 for Osa production. Molecular weight markers are listed at the left of each panel. Asterisk, crossreactive IgG heavy chain. Except for the *virE2* mutant, the A348 derivatives accumulated similar steady-state levels of VirE2 (data not shown); VirD4 overproduction in A348(pKA21) has been documented previously (Atmakuri *et al.*, 2003).

A

Donor	Transconjugants / donor cell
■ LBA4404 (pML122ΔKan)	1.1x10 ⁻⁴
▨ LBA4404 (pML122ΔKan, Osa)	1.9x10 ⁻⁵
▩ LBA4404 (pML122ΔKan, E2-GFP)	9.3x10 ⁻⁵
PC1000 (pML122ΔKan)	<1x10 ⁻⁸




Fig. 6. The pSa Osa protein blocks VirD4 receptor access to the pML122

A. Conjugative transfer frequencies of LBA4404 (Δ T-DNA) donor strains carrying IncQ plasmid pML122 Δ Kan without or with plasmids producing Osa protein (pUCD3960) or VirE2-GFP (pXZ66). Donors were mated with either WT A348 carrying plasmid pBBR1MCS (*Str^r*). PC1000 (Δ *virB* operon) carrying pML122 Δ Kan served as a donor in a control mating. Data are presented for a representative experiment.

B. Effects of the IncQ plasmid and derivatives on T-DNA transfer. Lower panel: TriIP data showing amplification of pTiAch5 *repAB* (Ct) and pML122 *mobA* (IncQ). Upper panel: QTrIP data showing levels of pML122 in the immunoprecipitates recovered with antibodies to VirD4 (left panels) and VirB9 (right panels).

Table 1

Effects of pML122 plasmid and Osa production on T-DNA and VirE2 translocation assessed by plant mixed infection assays.^a

T-strand donor ^b	VirE2 donor ^c	<i>K. daigremontiana</i> leaves	Tobacco leaf discs
<i>virE2</i>	–	–	0
–	ΔT-DNA	–	0
<i>virE2</i>	ΔT-DNA	+++	4.1 ± 0.6
<i>virE2</i> (pML122) ^d	–	–	0.2 ± 0
–	ΔT-DNA (pML122)	–	0
<i>virE2</i> (pML122)	ΔT-DNA	+	0
<i>virE2::carb</i> (pML122)	ΔT-DNA	+	0.2 ± 0.1
<i>virE2</i>	ΔT-DNA (pML122)	–	0.1 ± 0
<i>virE2</i> (pUCD3960) ^e	–	–	0
–	ΔT-DNA (pUCD3960)	–	0
<i>virE2</i> (pUCD3960)	ΔT-DNA	+	0
<i>virE2::carb</i> (pUCD3960)	ΔT-DNA	+	0.2 ± 0.1
<i>virE2</i>	ΔT-DNA (pUCD3960)	–	0
<i>virE2</i> (pSa) ^f	–	–	0
–	ΔT-DNA (pSa)	–	0
<i>virE2</i> (pSa)	ΔT-DNA	+	0
<i>virE2::carb</i> (pSa)	ΔT-DNA	+	0.9 ± 0.3
<i>virE2</i>	ΔT-DNA (pSa)	–	0

^aT-DNA and VirE2 donor strains were coinoculated on wounded *K. daigremontiana* leaves or tobacco leaf discs as described in the *Experimental procedures*. Results are expressed as sizes of tumours on *K. daigremontiana* leaves 5 weeks after inoculation [on a scale of no tumour (–) to WT tumour (+++)], or as an average number of tumours arising along the edges of tobacco 16 leaf pieces.

^b*virE2* – strain At12516 (Fullner, 1998) or *virE2::carb* (this study).

^cΔT-DNA – strain LBA4404 (Ooms *et al.*, 1982).

^dpML122, a derivative of RSF1010 (IncQ) (Fullner, 1998).

^epUCD3960, produces Osa from a constitutive *nptI* promoter (Chen and Kado, 1996).

^fpSa, produces Osa from its native promoter (Close and Kado, 1991).

Table 2Mobilization of pCloDF13 and RSF1010 derivatives between *Agrobacterium* strains.^a

Donor ^b	Transfer of:			
	RSF1010		CloDF13	
	C58C1RS ^c	UIA143 ^c	C58C1RS	UIA143
A348 (pML122 ^d)	2.3×10^{-4}	1.7×10^{-6}	NA	NA
A348 (pJClo)	NA	NA	6.4×10^{-5}	4.1×10^{-7}
A348 (pJClo, pML122 ^d)	8.9×10^{-5}	5.8×10^{-7}	2.1×10^{-5}	1.3×10^{-7}
A348 (pJClo, pUCD3960 ^f)	NA	NA	7.9×10^{-5}	4.9×10^{-7}
Mx355 (pML122 ^e)	$< 10^{-8}$	$< 10^{-8}$	NA	NA
Mx355 (pJClo)	NA	NA	0.9×10^{-4}	6.8×10^{-7}
KA2000 (pML122 ^d)	$< 10^{-8}$	$< 10^{-8}$	NA	NA
KA2000 (pJClo)	NA	NA	8.1×10^{-5}	6.0×10^{-7}
KA2000 (pJClo pML122 ^e)	$< 10^{-8}$	$< 10^{-8}$	7.7×10^{-5}	5.4×10^{-7}
KA2000 (pJClo, pUCD3960 ^f)	NA	NA	7.4×10^{-5}	5.7×10^{-7}

^aMatings were carried out on a solid surface for 4 days at 20°C, as described in the *Experimental procedures*. Results are expressed as transconjugants per donor (Tc's/donor).

^bDonor cells: WT A348; Mx355 or KA2000 (two independent *virD4* mutants).

^cRecipient cells: C58C1RS (carries Ti plasmid which stimulates plasmid DNA acquisition); UIA143 (Ti plasmidless). Mobilizable plasmids:

^dpML122ΔKan;

^epML122ΔGen; pJClo, a pCloDF13 derivative.

^fpUCD3960, constitutively synthesizes Osa protein.

NA, not applicable.